164 related articles for article (PubMed ID: 28880848)
1. Deflazacort (Emflaza) for Duchenne muscular dystrophy.
Med Lett Drugs Ther; 2017 Sep; 59(1529):153-154. PubMed ID: 28880848
[No Abstract] [Full Text] [Related]
2. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
McAdam LC; Mayo AL; Alman BA; Biggar WD
Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
[TBL] [Abstract][Full Text] [Related]
3. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up.
Merlini L; Gennari M; Malaspina E; Cecconi I; Armaroli A; Gnudi S; Talim B; Ferlini A; Cicognani A; Franzoni E
Muscle Nerve; 2012 Jun; 45(6):796-802. PubMed ID: 22581531
[TBL] [Abstract][Full Text] [Related]
4. Delandistrogene moxeparvovec (Elevidys) for Duchenne muscular dystrophy.
Med Lett Drugs Ther; 2023 Oct; 65(1686):159-160. PubMed ID: 37755693
[No Abstract] [Full Text] [Related]
5. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
[TBL] [Abstract][Full Text] [Related]
6. The impact of deflazacort on puberty in Duchenne muscular dystrophy.
Dooley JM; Bobbitt SA; Cummings EA
Pediatr Neurol; 2013 Oct; 49(4):292-3. PubMed ID: 23921283
[TBL] [Abstract][Full Text] [Related]
7. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Gloss D; Moxley RT; Ashwal S; Oskoui M
Neurology; 2016 Feb; 86(5):465-72. PubMed ID: 26833937
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroids and Duchenne muscular dystrophy: does earlier treatment really matter?
McDonald CM; Han JJ; Mah JK; Carter GT
Muscle Nerve; 2012 Jun; 45(6):777-9. PubMed ID: 22581529
[No Abstract] [Full Text] [Related]
9. Vertebral Fractures in Duchenne Muscular Dystrophy Patients Managed With Deflazacort.
Singh A; Schaeffer EK; Reilly CW
J Pediatr Orthop; 2018 Jul; 38(6):320-324. PubMed ID: 27328118
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
Wong BL; Christopher C
J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
[TBL] [Abstract][Full Text] [Related]
11. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
Alman BA; Raza SN; Biggar WD
J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
[TBL] [Abstract][Full Text] [Related]
12. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.
Moxley RT; Pandya S; Ciafaloni E; Fox DJ; Campbell K
J Child Neurol; 2010 Sep; 25(9):1116-29. PubMed ID: 20581335
[TBL] [Abstract][Full Text] [Related]
13. The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist.
Ames WA; Hayes JA; Crawford MW
Paediatr Anaesth; 2005 Jan; 15(1):3-8. PubMed ID: 15649156
[No Abstract] [Full Text] [Related]
14. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
[No Abstract] [Full Text] [Related]
15. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
[No Abstract] [Full Text] [Related]
16. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
Kim S; Campbell KA; Fox DJ; Matthews DJ; Valdez R;
J Child Neurol; 2015 Sep; 30(10):1275-80. PubMed ID: 25414237
[TBL] [Abstract][Full Text] [Related]
18. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.
Biggar WD; Harris VA; Eliasoph L; Alman B
Neuromuscul Disord; 2006 Apr; 16(4):249-55. PubMed ID: 16545568
[TBL] [Abstract][Full Text] [Related]
19. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy.
Silversides CK; Webb GD; Harris VA; Biggar DW
Am J Cardiol; 2003 Mar; 91(6):769-72. PubMed ID: 12633823
[No Abstract] [Full Text] [Related]
20. New Treatment for Duchenne Muscular Dystrophy.
Aschenbrenner DS
Am J Nurs; 2017 Jun; 117(6):22-23. PubMed ID: 28541984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
